Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients

Figure 1 Clinical remission rate. Combinational therapy with adalimumab and azathioprine significantly increased the clinical remission rate vs nonconcomitant use at week 24.

Figure 2 Mean Crohn’s disease activity index and C-reactive protein through week 24. A: Combinational therapy with adalimumab (ADA) and azathioprine (AZA) significantly reduced the Crohn’s disease activity index (CDAI), compared with nonconcomitant use at week 24. ^aP < 0.05 vs week 0; ^cP < 0.05 vs adalimumab; B: The concomitant use of AZA tended to maintain low C-reactive protein (CRP) levels for 24 wk (CRP levels at weeks 0 and 24 were 0.66 ± 0.73 and 0.27 ± 0.44, respectively, P = 0.09).